Biosimilars in Canada: The importance of moving from why to how
Presentation at Benefit Canada’s 2023 Face to Face Drug Plan Management Forum
December 5, 2023
The Canadian Biosimilars Forum had the privilege of joining forces with Neda Nasseri, Pharmacist, and Product Director for Drug Benefits at Desjardins, to delve into Desjardins’ unique approach to biosimilars.
Our goal was to transcend the WHY and focus on the HOW. Transitioning biosimilars into a pivotal element of private drug plans and showcasing the collaborative potential for benefits consultants, private payers, and plan sponsors to optimize and mutually benefit from the value of biosimilars.
Click to view our Presentation Slides.
Stay tuned for further coverage of the Benefits Canada event in the new year!
The Canadian Biosimilars Forum
The Canadian Biosimilars Forum is an alliance of companies who represent the breadth of the biosimilars industry and who are collectively working to increase awareness, access and adoption of biosimilars across Canada. Learn more about the Forum
5 Key Facts About Biosimilars
Biosimilars are safe and effective medicines that treat diseases like cancer, diabetes, arthritis and inflammatory bowel disease.
Patients can expect no difference in efficacy and safety following a routine switch to a biosimilar.
A well-controlled switch policy protects patient choice.
Biosimilars could deliver over a Billion dollars in savings per year to the Canadian health care system.
Governments can use savings to provide more patients with access to more treatments.